Twentyninc chronic schizophrenics maintained on trifluperazinc treatment were included in the trial trifluperazinc was discontinued till relapse oeeurcd. Standard injectable trifluperazinc was reinstituted for 10 days. This was replaced by weekly dose of 20-40 mg penfluridol orally for a period of d months. Assessment was done monthly and side effects were monitored. At the end of h months. 2M patients not only maintained but improved in the psychiatric status. The trial has confirmed that penfluridol is a safe and effective drug which would be suitable for maintenance therapy in schizophrenic patients.
Introduction
Since the introduction of Chlorpromazine by Delay and Deniker in early fifties the search for effective chemotherapeutic agents has not satisfied the satiety of scientists in the field. During this brief history more than hundred neuroleptics have been clinically investigated and approximately one quarter of these have been widely employed in clinical practice.
In long term management of schizophrenic patients studies indicate that stopping maintenance medication brings on a relapse. In two large controlled studies of released psychiatric patients 45-58% were rehospitalised within 2 years (Drieman PM et al 1979; Langsley et al 1971) . Hogarty and Goldberg (1973) reported from a large controlled aftercare study that significant inverse relationship existed between maintenance chemotherapy and rate of relapse in the community.
Long term drug taking has inherent problems of non-compliance. The schizophrenic process also interferes with proper intake of medication. Injectable depot preparations have been used, but have the disadvantage of provoking severe extrapyramidal reactions. Oral antipsychotics with a long duration of action have been possible alternative in the long search for an effective maintenance chemotherapeutic agent. Recent development of the diphenylbutyl piperidine series of drugs is a significant step in this direction.
Penfluridol is a long acting orally effective Diphenylbutylpiperidine in the class of pimozide and fluspirilene. Penfluridol has a biological half life of 130 hrs. and peak concentrations occur within 8 hrs. of injection (Askel Jorgenses 1983) . Thus penfluridol remains biologically active for between one and two weeks following a single oral dose (A.V.P. Mackay 1982) and is the longest acting (Lapierre 1978) . Penfluridol blocks central catecholamine receptors; especially dopamine receptors and thus makes it a right candidate as an antipsychotic drug.
Recent clinical studies in some centres in Europe and North America have shown that oral administration of penfluridol can provide a relatively safe and adequate control of schizophrenic patients with a duration of action of one week (Gallant et al 1974; Van Paraag et al 1971) .
The present study was designed to set the hypothesis that a) Penfluridol administered orally once a week in an effective agent in the maintenance therapy of schizophrenic patients and b) To compare its efficacy with that of Trifluoperazine.
Material and Methods
Twentynine patients who fulfilled the DSM III criteria for schizophrenia; (18 males and 11 females) ranging in age from 19 to 52 years were included in the 6 months trial. All the patients prior to their being admitted to the trial were under maintenance therapy with Trifluoperazine. At the beginning of the trial the patients were physically examined, routine blood investigations and Liver Function Tests were done. The design of the study was unique in that there was discontinuation of classical neuroleptic maintenance treatment till relapse occured. (Earlier studies switched to penfluridol abruptly after discontinuation of the classical neuroleptic therapy). Patients failing to relapse within four weeks were withdrawn from the study. The standard neuroleptic therapy was re-instituted with trifluoperazine 4 mg daily given deep I.M. for a period of 10 days. Parenteral trifluoperazine was used in order to bypass the enterohepatic circulation and thus improve the bio-availability of the drug. Trifluoperazine was replaced by weekly dose of 20-40 mg of penfluridol administered orally. The patients were assessed monthly on 36 items questionaire for a period of 6 months in relation to his/her pre-trial state and grouped under the following categoriesmarked improvement; maintained; deterioration. The factor composition of penfluridol protocol (from ECDEU assessment manual 1976) is given below: Side effects.
The analysis of individual patients mental status was subjected to statistical analysis based on a comparison by paired V test at the end of 6 months.
Results
Twelve patients showed marked and rapid improvement 16 had maintained their pretrial mental state i.e. they did not show any deterioration but were in a controlled state as they were under former neuroleptic treatment. Out of 29 patients only a single patient showed some signs of deterioration. Of the 16 patients who showed maintenance state -12 had duration of illness over 12 years.
On individual items it was noticed that there was a significant improvement in the reduction of somatic concern (P<0.05) and guilt feeling (P<0. Hostility and suspiciousness-There was an overall improvement in all the areas of suspiciousness; animosity and delusions (P«).01).
In addition, there was improvement in work capacity by reduction in social withdrawl and enhancement of positive attitude to work.
Side Effects
Side effects such as restlessness (6) moderate sedation (3), tremors (8), oculogyric crises (4), rigidity (1). and heavy sedation (1) were seen but they were less in comparison with previous therapy.
Discussion
The above results demostrate the superior effect of penfluridol over trifluoperazine. The global assessment showed that penfluridol was not only able to maintain but also improve the psychiatric status of 28 patients over a period of 6 months. However, it is difficult to state at this stage about its superiority over other neuroleptics. But with the contemporary trend towards outpatient care of schizophrenic patients the use of drugs like penfluridol may bring better reward by maintaining chronic schizophrenics in remission.
Otta, Kurland and Slotnick (1974) in a study evaluating the safety of penfluridolalso reportd a reasonably good level of therapeutic response to penfluridol. They found that 3 out of 4 items of the BPRS showed significant difference in favour of penfluridol on the items of excitation, thinking disorganisation and anergia. 5 of 6 factors in NOSIE as well as total score showed significant improvement in penfluridol provide safe and adequate control of chronic schizophrenics and displays efficacy similar to other antipsychotics.
BaroF Brugmans et al (1970) also found penfluridol safe and effective in psychiatric symptomatology. They used a dose range beginning from 5-10 mg upto a maximum of 160-200 mg and found that clinically significant effects on vital signs or different laboratory tests. Adverse reactions were no more frequent than among controlled patients receiving commonly used neuroleptic medication. EPSoccured at more than 10 mg doses; and sedation was virtually absent. Psychiatric tests (CCI. NOSIE & BPRS) showed the drug as effective as conventional phenothiazines used in their groups.
One
Indian study by Channabas; wanna and Albert Michael (1987) has also found that Penfluridol as once weekly oral dose provides adequate and safe control of schizophrenia.
As reported by Tanghc and Vereechen (1972) in our study also the side effects were mild in nature and could be easily controlled.
In conclusion penfluridol appears to be effective and safe drug and may prove useful as a maintenance medication. Penfluridol provides an additional choice in the therapeutic armamentarium of neuroleptics.
